Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 562-565

  Surman, Deborah R ^a   Dudley, Mark E ^a   Overwijk, Willem W ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNOLOGY;

EID: 0034650421     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.562     Document Type: Article

References (26)

1. Lengauer, C., K. W. Kinzler, and B. Vogelstein. 1998. Genetic instabilities in human cancers. Nature 396:643.
2. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:4155.
3. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi, 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
4. Huang, A. Y., A. T. Brace, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-I expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
5. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
6. Wang, M., V. Bronte, P. W. Chen, L. Gritz, D. Panicali, S. A. Rosenberg, and N. P. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recomhinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685.
7. Restifo, N. P. 1996. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8:658.
8. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.
9. Kalams, S. A., and B. D. Walker. 1998, The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199.
10. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96:2982.
11. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186: 2057.
12. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205.
13. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23:1094.
14. Asher, A. L., J. J. Mule, A. Kasid, N. P. Restifo, J. C. Salo, C. M. Reichert, G. Jaffe, B. Fendly, M. Kriegler, and S. A. Rosenberg. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227.
15. Overwijk, W.W., D. R. Surman, K. Tsung, and N. P. Restifo, 1997. Identification of a Kb-restricted CTL epitope of beta-galaclosidase: potential use in development of immunization protocols for "self" antigens. Methods 12:117.
16. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitaled rejection of murine B16 melanomas. J. Immunol. 161:897.
17. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146:3235.
18. + anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Cell Immunol. 178:79.
19. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122.
20. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
21. Melief, C. J., and W. M. Kast. 1995. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145:167.
22. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277.
23. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief, 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
24. + T-helper and a T-killer cell. Nature 393: 474.
25. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
26. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. [Published erratum appears in 1996 J. Exp. Med. 184:1591.] J. Exp. Med. 184:741.